Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (842)	2/18/2005 3:12:26 PM
From: Ian@SI	Read Replies (1) \| Respond to of 3722

Bernard, Can you make any comments on ARQL's chart? Specifically, would you expect price to hit the $3.95 - $4.00 range? ... or might it find support in the $4.36- $4.40 range? Volume seems to have picked up this year relative to the prior 6 months while money flow has gone from +.29 on January 4th to -.226 today. Prior troughs for this measure bottomed at about -.45 to -.50 on the Money Flow chart that I can see. Prior instances of money flow worse than -.2 seem to result in the trough values before reversing. RSI is now 29.3. Prior bottoms were near about 18 in Feb 03; and 24.5 last July. Last October, it turned around after hitting 33. This seems to have gone straight down since about Feb 9th. (Earnings report, Secondary) All of this just leaves me confused. Any TA expertise you could share will be appreciated. Thanks, Ian

To: Jibacoa who wrote (842)	7/18/2005 10:15:39 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

MLNM Is going over its June 20 H of 10.01 and hasn't bothered to close its June 17 upgap.<g> bigcharts.marketwatch.com Last Monday it announced that it was starting a PII of MLN1202, its humanized monoclonal antibody, in patients with relapsing-remitting MS MLN1202 is supposed to block CCR2 chemokine receptors and to prevent the infiltration of immune cells into inflammatory sites. MLNM Reportedly has around $1.85 in cash/shr and is expected to cut its loss to $0.35/shr vs. $0.59 in 2004 and for 2006 a further cut is expected to $0.07/shr.<g> Bernard